Uprosertib

Drug Overview

Uprosertib represents a significant advancement in the field of precision oncology. It is a specialized medical agent designed to interfere with the internal “engines” that drive the growth and survival of cancer cells. In the medical community, uprosertib is recognized as a Targeted Therapy and a “Smart Drug.” Unlike traditional chemotherapy, which broadly attacks all fast-growing cells, targeted therapies like uprosertib are engineered to find and block specific molecules that are unique to, or overactive in, cancer cells.

For patients and healthcare professionals, uprosertib offers a strategic approach to treating tumors that have become resistant to other therapies. It is particularly valued for its ability to target a specific signaling pathway that is often “hijacked” by aggressive cancers. By shutting down this pathway, the drug aims to stop the cancer from spreading and to make the tumor cells more vulnerable to other treatments.

• Generic Name: Uprosertib (also known as GSK2141795).
• US Brand Names: None (Currently an investigational drug).
• Drug Class: Akt Inhibitor (specifically an ATP-competitive inhibitor of Akt 1, 2, and 3).
• Route of Administration: Oral (Capsules taken by mouth).
• FDA Approval Status: Investigational. It is currently being studied in Phase I and Phase II clinical trials and has not yet received full FDA approval for general commercial use.

What Is It and How Does It Work? (Mechanism of Action)

To understand how uprosertib works, one must look at the “control center” of a cancer cell. Cells rely on complex signaling pathways to know when to grow, when to divide, and when to die. One of the most critical pathways in cancer is the PI3K/Akt/mTOR pathway.

The Role of Akt

Akt is a protein kinase, which is essentially a molecular switch. In a healthy body, Akt helps regulate cell metabolism and survival. However, in many types of cancer, this switch gets stuck in the “ON” position. When Akt is overactive, it sends constant, frantic signals to the cell to keep growing and to ignore the body’s natural signals to die.

Molecular Level Activity

Uprosertib is designed to be a highly selective and potent inhibitor of all three forms of the Akt protein (Akt 1, 2, and 3). It works through a process called “ATP-competitive inhibition.”

1. Binding to the Pocket: Every Akt protein has a specific “pocket” where it captures a molecule called ATP. The protein uses ATP as fuel to send its growth signals.
2. Blocking the Fuel: Uprosertib is shaped to fit perfectly into that same pocket. By sitting in the pocket, it prevents the Akt protein from accessing its ATP fuel.
3. Shutting Down the Signal: Without fuel, the Akt “switch” is forced into the “OFF” position. This stops the flow of messages through the PI3K/Akt/mTOR pathway.
4. Inducing Apoptosis: When the growth signals stop, the cancer cell experiences a state of crisis. This often triggers apoptosis, or programmed cell death. Essentially, the drug forces the cancer cell to realize it is broken and should self-destruct.

By acting as a molecular roadblock, uprosertib can slow or stop the progression of tumors that rely heavily on this specific “engine.”

FDA Approved Clinical Indications

As an investigational agent, uprosertib does not yet have official FDA-approved “labels” for routine clinical practice. However, it is being utilized in approved clinical research trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Ovarian Cancer: Often studied in combination with other drugs like trametinib for patients with recurrent or resistant disease.
• Triple-Negative Breast Cancer: Investigated for cases where the PI3K/Akt pathway is mutated.
• Melanoma: Targeted at advanced cases that have stopped responding to standard BRAF inhibitors.
• Solid Tumors: Used in early-phase research for various advanced cancers that show specific genetic markers.

Non-oncological Uses:

• There are currently no identified non-oncological uses for uprosertib; its development is focused entirely on oncology.

Dosage and Administration Protocols

Uprosertib is an oral medication, which provides patients with the convenience of at-home treatment compared to intravenous infusions. Because it is an investigational drug, the dose is strictly controlled within the context of clinical trials.

Dose Adjustments

• Hepatic/Renal Insufficiency: Since the drug is processed primarily by the liver, patients with significant liver damage (elevated AST/ALT or bilirubin) may require a dose reduction of 25% to 50% or may be excluded from certain trials for safety.
• Toxicity Management: If a patient develops severe side effects (such as high blood sugar or a severe rash), the doctor may “pause” the drug for a week and then restart it at a lower dose level.

Clinical Efficacy and Research Results

Clinical data from 2020 to 2025 has focused on how uprosertib performs when combined with other “Targeted Therapies.”

Key Research Findings

• Combination Efficacy: In Phase II trials for recurrent ovarian cancer, uprosertib combined with the MEK inhibitor trametinib showed a Clinical Benefit Rate (tumor shrinkage or stability) in approximately 28% to 35% of patients who had failed standard platinum-based chemotherapy.
• Disease Progression: Data indicates that for patients with specific PIK3CA or AKT1 mutations, uprosertib can extend “Progression-Free Survival” by an average of 3 to 5 months compared to historical data for single-agent chemotherapy in similar populations.
• Biomarker Success: Research suggests that patients whose tumors have a “hyper-activated” Akt pathway respond significantly better to this drug, supporting the move toward Personalized Medicine.

Safety Profile and Side Effects

Uprosertib has a unique safety profile because Akt is involved in many bodily functions, including how we process sugar.

Black Box Warning

• There is no formal FDA Black Box Warning for uprosertib. However, it carries significant warnings for Severe Hyperglycemia (high blood sugar) and Gastrointestinal Toxicity.

Common Side Effects (>10%)

• Hyperglycemia: A rise in blood sugar because Akt helps insulin work. Patients often need to monitor their glucose levels.
• Diarrhea: Frequent or loose stools, which is a common effect of many kinase inhibitors.
• Nausea/Vomiting: Usually mild to moderate and manageable with standard medications.
• Skin Rash: Acne-like or red rashes on the face and torso.

Serious Adverse Events

• Grade 3/4 Hyperglycemia: Extremely high blood sugar that may require insulin treatment.
• Severe Dehydration: Usually resulting from uncontrolled diarrhea.
• Pneumonitis: A rare but serious inflammation of the lung tissue.

Management Strategies

• Glucose Control: Many patients are started on metformin (a diabetes medication) to keep blood sugar stable while on uprosertib.
• Hydration: Patients are encouraged to drink at least 2 liters of water daily to prevent kidney stress.
• Early Reporting: Patients must report any new shortness of breath or persistent diarrhea immediately to their oncology team.

Research Areas

In the fields of Immunotherapy and Regenerative Medicine, uprosertib is being studied for its role in the “Tumor Microenvironment.” Scientists believe that by blocking the Akt pathway, they can make the tumor “visible” again to the immune system.

Current research is looking at combining uprosertib with Checkpoint Inhibitors (like PD-1 blockers). The goal is to use uprosertib to stop the tumor’s growth while the immunotherapy helps the body’s own T-cells find and destroy the cancer. Additionally, researchers are exploring how Akt inhibition affects the survival of healthy stem cells during chemotherapy, aiming to find ways to protect normal tissue while aggressively targeting the cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Genetic Profiling: To confirm the tumor has the specific Akt or PI3K markers.
• A1C and Fasting Glucose: To check the patient’s baseline blood sugar health.
• Liver Function Tests: To ensure the liver can safely process the drug.

Precautions During Treatment

• Monitor Blood Sugar: Patients, even those without diabetes, should use a home glucose monitor during the first few weeks of treatment.
• Sun Protection: The drug can make skin more sensitive; use SPF 50+ and protective clothing.

“Do’s and Don’ts” List

• DO take the medication exactly as prescribed, even if you feel better.
• DO keep a “diarrhea diary” to track how many stools you have each day.
• DON’T ignore extreme thirst or frequent urination, as these are signs of high blood sugar.
• DON’T take any new herbal supplements (like St. John’s Wort) without asking your doctor, as they can interfere with the drug.
• DON’T skip blood test appointments; these are vital for your safety.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Uprosertib is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general commercial use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.